Bivalirudin and Desmopressin Market Analysis

  • Report ID: 266
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Bivalirudin and Desmopressin Market Analysis

The global bivalirudin and desmopressin market is segmented and analyzed for demand and supply by application into percutaneous coronary intervention (PCI) procedures, percutaneous transluminal coronary angioplasty (PTCA) procedures, and others. Among these, the percutaneous coronary intervention (PCI) procedure segment is anticipated to capture the largest market size in the global bivalirudin and desmopressin market owing to the rising incidences of adverse cardiovascular (CVDs) and heart diseases among population. For instance, cardiovascular disease (CVD) was the leading cause of death in the United States in 2018, followed by stroke (17%), high blood pressure (11%), heart failure (9.5%), arteries diseases (3%), and other CVD (17.2%). PCI procedures are intended to reduce adverse cardiovascular diseases. PCI is further enhanced by antithrombotic and antiplatelet therapies as an adjunct to reduce MACE rates. This factor is expected to fuel the segment growth during the forecast period.  

Our in-depth analysis of the global bivalirudin and desmopressin market includes the following segments:

By Application

  • Percutaneous Coronary Intervention (PCI) Procedures
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 266
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Bivalirudin and Desmopressin Market size is projected to growing at around 5.1% CAGR during the forecast period i.e., between 2025-2037.

Rising prevalence of cardiovascular diseases along with increasing number of elderly people suffering from nocturia will impel the market growth.

North America industry is expected to hold largest revenue share by 2037, as coronary artery disease (CAD) prevalence among the population resulted in increasing percutaneous coronary intervention (PCI) procedures in the region.

The major players in the market are Pfizer, Inc., Hainan Shuangcheng Pharmaceuticals Co. Ltd., AmbioPharm Inc., Abott India Limited, The Medicines Company, Sun Pharmaceuticals Industries Limited, Ferring Pharmaceuticals, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample